News & Updates
Showing Multidisciplinary articles
Showing

RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer
Real-world (RW) data presented at ASCO GU 2026 support the use of enfortumab vedotin plus pembrolizumab (EV+P) as frontline treatment for advanced urothelial carcinoma (UC).
RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer
12 Mar 2026
Air pollution ups risk of Alzheimer’s disease
Exposure to fine particulate matter PM2.5 may elevate the risk for Alzheimer’s disease (AD), mainly through direct pathways instead of mediation by common comorbidities, suggests a study.
Air pollution ups risk of Alzheimer’s disease
11 Mar 2026
Belzutifan-lenvatinib bests cabozantinib for RCC
A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.
Belzutifan-lenvatinib bests cabozantinib for RCC
11 Mar 2026
PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC
Addition of palbociclib to maintenance therapy yielded a median progression-free survival (mPFS) approaching 4 years, representing an effective first-line (1L) treatment for patients with hormone receptor–positive (HR+), HER2-positive (HER2+) metastatic breast cancer (mBC), according to the phase III PATINA trial.





